(RTTNews) - Pulse Biosciences Inc.'s (PLSE) CellFX System has received Investigational Device Exemption approval from the FDA and a pivotal study evaluating this device in the treatment of sebaceous ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that clinical results from ...

The FDA has granted 510(k) clearance to Pulse Biosciences Inc's (NASDAQ: PLSE) CellFX System, expanding the indication for use to include the treatment of sebaceous hyperplasia in patients with ...

Sebaceous hyperplasia is most common in middle-aged or older people, particularly those with fair skin who have had a lot sun exposure. There is currently no cure for sebaceous hyperplasia. Some ...

Generally the result of age- related decreases in androgen production, sebaceous hyperplasia is characterized by common asymptomatic papules. The condition occurs most frequently in healthy ...

This patient had sebaceous hyperplasia, a benign proliferation of the sebaceous gland that occurs in a periorbital location on patients of middle age or older. The condition is characterized by small, ...

Please provide your email address to receive an email when new articles are posted on . Pulse Biosciences has announced it received FDA 510(k) clearance for expanding the use of its CellFX System to ...

(RTTNews) - Pulse Biosciences, Inc. (PLSE), a bioelectric medicine company, has received FDA clearance for its CellFX System to expand the indication for use in the treatment of sebaceous hyperplasia ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that one oral ...